We will quote to you the news of the best health sites Like : "indiatimes" and the most famous medical experts : Divya Rajagopal
daily : 2017-01-01 & on time : 11:35
referring to
Activists cry foul over new HIV drug monopoly
image uploaded by "indiatimes" site
MUMBAI: Doctors and aid organisations have called upon the Competition Commission of India and the price regulator to step in to ward off the monopoly over a new HIV drug, dolutegravir, which received the approval of the Indian drug controller last month.Dolutegravir — sold by GlaxoSmithKline's Viiv Healthcare unit under the Trivicay brand — is considered the best-in-class HIV drug as it reduces virus levels faster and has a high barrier to resistance compared to previous line of drugs.However, only one Indian drug maker, Emcure, will be allowed to sell the medicine in the Indian private market , because of a licensing agreement with Viiv Healthcare under the Medicine Patent Pool.This is despite Indian generic makers like Cipla Aurobindo Pharma , Hetero and Strides Arcolab having licence to sell this drug in nearly 50 other low- and middle-income countries.However, these companies can sell the drug through public sector tenders or through NGOs in India.Activists call this condition restrictive and anticompetitive.
about the details read more from here
Bill and Melinda Gates are now backing a tiny implantable drug pump from Intarcia designed to prevent HIV infection — Quartz
image uploaded by "qz" site
In sub-Saharan Africa, the human immunodeficiency virus (HIV) is an epidemic that shows no signs of relenting.In 2013, an estimated 24.7 million people in the region were living with HIV, accounting for 71% of the global total.Worldwide, 2.1 million people became newly infected with HIV in 2015, according to UNAIDS.
about the details read more from here
First human trials of long-acting injectable drug to prevent HIV underway / LGBTQ Nation
image uploaded by "lgbtqnation" site
A study that's been called the first large-scale clinical trial of an injectable drug for HIV prevention — one that will remain effective for a far longer period than the daily PrEP regimen — is now underway.It involves 4,500 men who have sex with men, as well as transgender women who have sex with men.They hail from 45 spots around the world: eight countries in the Americas, Asia and Africa.
about the details read more from here
HIV prevention: New injectable drug for PrEP could be a 'game-changer'
image uploaded by "ibtimes" site
A clinical trial has just been launched to test the efficacy of a new injectable drug to protect men who have sex with men and transgender women from becoming infected with HIV.Known as the HPTN 083 study, it aims to improve the prevention tools available to the demography that are most vulnerable to the virus.HIV pre-exposure prophylaxis is a preventive measure that involves people who are at very high risk for HIV – such as sexually active gay men – taking a combination of two oral HIV medicines sold under the name Truvada, on a daily basis.
about the details read more from here
To follow all the new news about
No comments:
Post a Comment